Compare Inovio Pharmaceuticals Inc (INO) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wendys Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Wendys Co trades at $7.81 (market cap $1.50B). The key difference: Wendys Co is far larger — about 16.8× Inovio Pharmaceuticals Inc's market cap, and Wendys Co pays a 7.13% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WEN | |
|---|---|---|
Market Cap | $89.27M | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $11.33 |
52-Week Low | $1.05 | $6.17 |
Enterprise Value | $60.28M | $5.31B |
Dividend Yield | — | 7.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Wendy's (WEN) trades at $7.805, up 0.58% with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics with P/E of 10.07 and P/S of 0.68, though net margins have declined to 6.77%. Recent news highlights Project Fresh initiatives and China expansion plans, while the company maintains a $0.14 dividend payment scheduled for June 2026.
WEN presents a mixed outlook with strong valuation appeal and dividend yield offset by margin pressures and declining earnings. The stock's 28% monthly gain reflects retail investor enthusiasm, but fundamental challenges require careful monitoring of turnaround execution and competitive positioning in the crowded fast-food sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
